India: Strict Examination Criteria Needed For Drug Patents

Last Updated: 17 January 2019
Article by Lokesh Vyas


Patentability of pharmaceutical drugs and other issue associated with the patent have been a moot point all over the world. Like other developing countries, India has also started granting patent rights to pharmaceutical drug products since the year 2005. The biggest concern that comes up in this scenario is of 'Ever greening strategies' which are dealt in section 3(d) of the Indian Patent Act, 1970. The said section proscribes the grant of patent to a new form of a known substance unless it substantially enhances the therapeutic efficacy of the drugs. Thus, the need to strike a balance between public rights i.e. drugs accessibility and private rights of innovative companies gets redoubled. Furthermore, 'the standard of therapeutic efficacy' is also a moot point and poses a bigger question to the judiciary and other competent authorities while granting or denying Patent protection.

Thus, it is very important to set the rigorous patentability standards for granting patent on a particular drug otherwise its repercussion will not only be detrimental to the general public (esp. patients) but also to the entire patent arena in the form of extended absolute monopolization period, exploitation of other competitors, and more importantly as an impediment the production of generic drug and causes delay of entrance of generic drugs in the market.

Irony of Malaysia's patented drugs

A pharmaceutical company famous for its HIV/AIDS drug which combines Lopinavir and Ritonavir did not file for patents on the two base compounds in Malaysia. However, from 1999 to 2006, several secondary patents were granted on the base compounds by the Malaysian intellectual property office. All over the world, the base compounds for patents for Lopinavir and Ritonavir have expired between 2014 and 2017 but in Malaysia, last secondary patent will expire in 2027 (Here). It shows that even after the expiration of base compounds in Malaysia and other counties, the patent life of the drug has increased by 10-12 years. As a result, availability of a generic version of such drugs remains a far cry in Malaysia. One unavoidable issue that arises due to such scenario is the high prices of HIV/AIDS drugs as per the Malaysian Competition Commission review of the pharmaceutical sector.

While citing the data of Malaysian health ministry, it was shown that the patented drug costed US$1,489 (RM6,112) per patient per year under a Health Ministry procurement contract, whereas a generic version of such drug can be obtained at US$268 (RM1,100) from India.

Like other IP countries, Malaysia also needs to ensure that drug patent application has an invention which is new, involves an inventive step and is capable of industrial application. But such criteria or standard is not defined in a country, the ultimate repercussions would be negative such as extended monopoly period which would further create an impediment for a generic version of drugs from entering the market.

The above argument brings our attention to the commonly used strategy of pharmaceutical companies called 'patent ever greening'. It is referred to the practice whereby pharmaceutical firms extend the patent life of a drug by obtaining additional 20-year patents for minor reformulations or other iterations of the drug, without necessarily increasing the therapeutic efficacy and thus gets multiple secondary over a pharmaceutical compound.

Therefore, it is essential for the ministry for IP and the patent office to come up with more stringent patentability criteria for pharmaceutical patent applications in order to avoid the practice of secondary patents and patent ever greening.

Notably, the data from the US Food and Drug Administration show a decline in the number of chemical entities for medicines since 1994 but at the same time, it reveals that there is an increase in number of registration of patent (Here). This growth in pharmaceutical patents is a problem in not only in the developed countries but also in the developing countries said Ms Sangeeta, legal advisor Third World Network. In furtherance of the same, an Inquiry by the European Commission in 2009 unveiled that in relation to 219 drugs, out of the 40,000 patents applications granted and pending, 87% were secondary patents, Ms. S. Sangeeta added. She further said that the delay in the entry of generic versions cased a loss of around 3 billion Euro.

While extolling the patentability criteria of Pharmaceutical drugs in India and Argentina, she added that weak patentability criteria for pharmaceutical patent applications leads to inaccessibility of life-saving drugs to the needy patients because of its unaffordable prices.

Considering "patents ever greening" cases and other detrimental strategies of Pharmaceutical companies in 2016, it was recommended by the Report of the United Nation Secretary General's High Level Panel on Access to Medicines that WTO Members should adopt and apply rigorous definitions of invention and patentability that are in the best interests of the public health of the country and its inhabitants to curtail the ever greening of patents, and to award patents only when genuine innovation has occurred. Condemning court process as time consuming and expensive, Ms S. Sangeeta proposed guiding measures for Malaysia stating that it should introduce administrative pre- and post- grant oppositions system to patents. Such a mechanism would ensure a more rigorous examination of patent applications and thereby generates better examination practices. Moreover, it would allow an interested party (generic companies or patient groups etc.) to oppose the application before the patent is granted and similarly post opposition allows any party to oppose a patent application after the grant of patent. This is how it will be helpful for the patients diagnosed with cancer, Hepatitis C, and rare diseases whose treatment is a far cry for such people because of their high pricing.

With respect to India patent scenario, the following shows the patent trends between 2012-2017 ( Here):-


( Here)


( Here)


The grant of patent connotes monopoly over the patented subject matter and if it is granted so easily without applying firm standards and tests, it would not harmonize the purpose of IP law. The objective of IP law is to provide incentives to create and serve the interests of the public by promoting economic growth. Interestingly, in pharmaceutical sector, the rigorous application of patentability standards becomes more important because the production of medicines depends upon them. Thus, their direct nexus with the public health which constitutes a part of public interest cannot be overlooked. So if the ever greening strategies which ultimately extends the monopoly time, are not curbed, the result will be unaffordable high prices of the medicines and delay in the entrance of generic drugs in the market. High pricing of the medicine are accessible to only a limited number of people who are rich but the large segment of the people who cannot afford such high pricing medicines have to suffer by relying on their fate. Thus, the role of patentability standards is very significant in the pharmaceutical sectors.




The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions